Wealth Advisors Northwest LLC Invests $239,000 in Eli Lilly and Company $LLY

Key Points

• Wealth Advisors Northwest LLC invested $239,000 in 307 shares of Eli Lilly and Company (NYSE:LLY) during the second quarter, showcasing growing interest from institutional investors.
• Director Gabrielle Sulzberger and J Erik Fyrwald recently purchased shares of Eli Lilly, indicating confidence in the company's performance, as insiders have bought a total of 4,514 shares worth $2,894,841 over the last quarter.
• Eli Lilly's earnings report exceeded expectations with $6.31 EPS for the quarter, alongside a revenue of $15.56 billion—up 37.6% compared to the same quarter last year.

Wealth Advisors Northwest LLC acquired a new position in Eli Lilly and Company (NYSE:LLY - Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 307 shares of the company's stock, valued at approximately $239,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Precedent Wealth Partners LLC boosted its holdings in Eli Lilly and Company by 15.3% during the 2nd quarter. Precedent Wealth Partners LLC now owns 294 shares of the company's stock valued at $229,000 after acquiring an additional 39 shares during the period. Capital Advisors Inc. OK boosted its holdings in Eli Lilly and Company by 6.8% during the 2nd quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company's stock valued at $5,260,000 after acquiring an additional 429 shares during the period. Family CFO Inc purchased a new stake in Eli Lilly and Company during the 2nd quarter valued at about $54,000. Duquesne Family Office LLC boosted its holdings in Eli Lilly and Company by 52.5% during the 1st quarter. Duquesne Family Office LLC now owns 94,830 shares of the company's stock valued at $78,321,000 after acquiring an additional 32,640 shares during the period. Finally, Corient IA LLC purchased a new stake in Eli Lilly and Company during the 1st quarter valued at about $570,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Gabrielle Sulzberger bought 117 shares of the stock in a transaction dated Tuesday, August 12th. The stock was bought at an average price of $641.18 per share, for a total transaction of $75,018.06. Following the purchase, the director directly owned 2,703 shares in the company, valued at $1,733,109.54. This trade represents a 4.52% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director J Erik Fyrwald acquired 1,565 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the transaction, the director owned 74,578 shares in the company, valued at $47,903,686.74. This represents a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought a total of 4,514 shares of company stock worth $2,894,841 over the last quarter. Company insiders own 0.13% of the company's stock.

Eli Lilly and Company Trading Up 1.0%

LLY opened at $854.40 on Friday. The stock has a market cap of $808.66 billion, a PE ratio of 55.84, a PEG ratio of 1.18 and a beta of 0.47. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The business has a 50 day moving average of $740.99 and a 200-day moving average of $766.49. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $937.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm's revenue for the quarter was up 37.6% compared to the same quarter last year. During the same quarter last year, the business posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

LLY has been the subject of several analyst reports. Leerink Partners restated a "market perform" rating and set a $715.00 target price on shares of Eli Lilly and Company in a report on Thursday, August 7th. Daiwa America cut Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Sunday, August 17th. DZ Bank upgraded Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 14th. Guggenheim increased their price objective on Eli Lilly and Company from $875.00 to $948.00 and gave the stock a "buy" rating in a report on Wednesday. Finally, UBS Group dropped their price objective on Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating for the company in a report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $948.56.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.